Ashling Wahner

Toni Choueiri, MD, discusses the unique features of NKT2152, the agent’s safety profile in RCC, and future research directions across GU oncology.

The FDA approved T-DXd for unresectable/metastatic HR+, HER2-low/-ultralow breast cancer that progressed on endocrine therapy in the metastatic setting.

Detectable ctDNA after neoadjuvant chemotherapy was associated with the recommendation for TME in patients with T1-3, N0 low or mid rectal cancer.

The EMA has accepted for review an MAA seeking the approval of nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with CIS.

ctDNA positivity was associated with worse DFS overall but significantly better DFS with celecoxib vs placebo in stage III resected colon cancer.

Zoldonrasib was well tolerated and associated with manageable AEs and preliminary antitumor activity in patients with KRAS G12D–mutated PDAC.

Galinpepimut-S demonstrated early efficacy signals in patients with acute myeloid leukemia in second complete remission or later.

David Rimm, MD, PhD, discusses pathology limitations that have been exacerbated by the current lineup of breast cancer IHC tests.

The FDA has granted a breakthrough device designation to the DCISionRT test for patients with breast cancer with ductal carcinoma in situ.

Frontline dostarlimab plus chemotherapy has been approved in the EU for all adult patients with primary advanced or recurrent endometrial cancer.

The addition of pembrolizumab to preoperative radiation therapy followed by surgery prolonged DFS in patients with soft tissue sarcoma of the extremity.

Tovorafenib generated durable drug holiday responses in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma.

LOAd703 has been granted FDA fast track designation for the treatment of patients with pancreatic cancer.

The FDA has approved acalabrutinib plus bendamustine and rituximab for adult patients with previously untreated MCL who are ineligible for autologous HSCT.

An NDA has been submitted to the FDA seeking the approval of TAR-200 for BCG-unresponsive high-risk NMIBC with CIS, with or without papillary tumors.

Marlise Luskin, MD, MSCE, discusses the treatment paradigm for relapsed/refractory ALL and research seeking to integrate agents into the frontline setting

Patients with treatment-naive CLL who received the BOVen regimen had an increased likelihood of achieving uMRD levels in peripheral blood and bone marrow.

Naseema Gangat, MBBS, discusses the role of rusfertide for decreasing phlebotomy needs and the potential future for disease-modifying PV management.

The NCCN Guidelines for B-Cell Lymphomas were updated to include ctDNA testing for MRD assessment for patients with PET-positive DLBCL at end of treatment.

Naseema Gangat, MBBS, discusses clinical factors that she uses to choose the optimal JAK inhibitors for individual patients with myelofibrosis.

Frontline belzutifan plus cabozantinib elicited durable responses and was tolerable in patients with treatment-naive advanced ccRCC.

A marketing authorization application has been submitted to the EMA seeking the approval of eflornithine for patients with high-risk neuroblastoma.

The FDA has granted priority review to sunvozertinib for advanced/metastatic NSCLC with EGFR exon 20 insertion mutations after progression on chemotherapy.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in December 2024.

China's NMPA has approved taletrectinib adipate capsule for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC.

A series of events took John L. Marshall, MD, down his path of becoming a gastrointestinal oncology leader, with a drive that has also solidified him on the patient journey and enhancing their quality of care.

Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.

The FDA granted fast track designation to NX-5948 for Waldenstrom macroglobulinemia that is relapsed/refractory to at least 2 lines of therapy.

Pembrolizumab plus chemotherapy, followed by olaparib with or without bevacizumab, improved PFS in advanced ovarian cancer.

Blinatumomab plus chemotherapy significantly improved 3-year DFS rates vs chemotherapy alone in pediatric patients with standard-risk pediatric B-ALL.